A new article entitled “Lived time and the affordances of clinical research participation” has recently been published in the journal Sociology of Health & Illness. In this article, authors address the problem of participation and the dominant focus on motivations in clinical research. They explore participation as a relational mode of ‘being in time’ in…
DetailsOn 17 November 2020, a coalition of partners including the US Alzheimer’s Association, Gates Ventures and the Wellcome Trust launched the Alzheimer’s Disease Data Initiative (ADDI) and its Alzheimer’s Disease (AD) Workbench. Designed as a platform for federated data sharing, the AD Workbench aims to facilitate interoperability across existing data platform, by enabling researchers to…
DetailsThe EPAD BioRepository team has recently successfully sent 3,000 samples for RNA analyses in Germany. These samples were collected annually from research participants throughout their participation in the EPAD Longitudinal Cohort Study. Once analyses are complete, the data will be integrated into the main EPAD database, accessible via the Alzheimer’s Disease Workbench of the Alzheimer’s…
DetailsThe EFSPI 6th Regulatory Statistics Workshop was held online from 13-15 September. This workshop discussed opportunities and challenges of statistical topics between regulators, academics, and industry. Philip Hougaard from Lundbeck presented the EPAD project, with an oral presentation entitled “Designing the EPAD trial platform: key issues”. In his talk, he gave an overview of the…
DetailsA new article from the EPAD consortium entitled “Disease modelling of cognitive outcomes and biomarkers in the European Prevention of Alzheimer’s Dementia Longitudinal Cohort” has recently been published in the journal Frontiers in Big Data. Abstract: A key challenge for the secondary prevention of Alzheimer’s dementia is the need to identify individuals early on in…
DetailsOn 1 July, the Alzheimer’s Disease Data Initiative (ADDI) released its first ever newsletter, in which EPAD is featured as a key partner and the first project to place its entire dataset onto the Alzheimer’s Disease Workbench. From January 2015 until February 2020, the EPAD Longitudinal Cohort Study (LCS) screened over 2,000 participants across nine…
DetailsOn 17 June, an online EPAD–AMYPAD imaging workshop was organised, aiming to engage researchers across the scientific community in the ongoing analyses currently performed in these two large European consortia, funded by the Innovative Medicines Initiative (IMI). Through these two projects, an abundance of longitudinal MR and amyloid PET imaging data in a pre-dementia Alzheimer’s…
DetailsA new article from the EPAD consortium entitled “”Ready for What?”: Timing and Speculation in Alzheimer’s Disease Drug Development” has recently been published in SAGE Journals. In this paper, authors examined challenges of time and recruitment in the context of the move to precision or stratified medicine, focusing on “readiness”: the state of being ready…
DetailsAs previously announced, the latest and final EPAD dataset called Version.IMI (V.IMI) is now available in the Alzheimer’s Disease Workbench to provide even greater value to the global neuroscience research community. All the data collected and processed annually during the IMI period of EPAD from research participants throughout their participation in the Longitudinal Cohort Study…
DetailsA new article from the EPAD consortium entitled “Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort” has recently been published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association. In this article, the ATN classification was operationalized in the first 1500 participants consented in the EPAD…
Details
